AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 214 filers reported holding AGIOS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,466,165 | -20.9% | 59,239 | -9.5% | 0.00% | 0.0% |
| Q2 2023 | $1,854,394 | -27.2% | 65,480 | -40.9% | 0.00% | -50.0% |
| Q1 2023 | $2,546,592 | +38.4% | 110,866 | +69.1% | 0.00% | +33.3% |
| Q4 2022 | $1,840,588 | -100.0% | 65,548 | -54.0% | 0.00% | -50.0% |
| Q3 2022 | $4,027,270,000 | +79.8% | 142,407 | +41.0% | 0.01% | +100.0% |
| Q2 2022 | $2,239,791,000 | +172.8% | 101,028 | +258.2% | 0.00% | +200.0% |
| Q1 2022 | $821,135,000 | -29.8% | 28,208 | -20.8% | 0.00% | -50.0% |
| Q4 2021 | $1,170,205,000 | -8.5% | 35,601 | +28.4% | 0.00% | 0.0% |
| Q3 2021 | $1,279,370,000 | +13.6% | 27,722 | +35.6% | 0.00% | +100.0% |
| Q2 2021 | $1,126,559,000 | +19.9% | 20,442 | +12.3% | 0.00% | 0.0% |
| Q1 2021 | $939,900,000 | +0.9% | 18,201 | -15.3% | 0.00% | -50.0% |
| Q4 2020 | $931,248,000 | -78.6% | 21,492 | -82.7% | 0.00% | -66.7% |
| Q3 2020 | $4,354,595,000 | -50.6% | 124,417 | -24.6% | 0.01% | -62.5% |
| Q2 2020 | $8,821,205,000 | +45.7% | 164,944 | -3.3% | 0.02% | +33.3% |
| Q1 2020 | $6,053,633,000 | -56.2% | 170,621 | -41.0% | 0.01% | -52.0% |
| Q4 2019 | $13,820,092,000 | +2591.3% | 289,426 | +1726.1% | 0.02% | +2400.0% |
| Q3 2019 | $513,508,000 | -24.8% | 15,849 | +15.7% | 0.00% | 0.0% |
| Q2 2019 | $683,306,000 | -26.2% | 13,699 | -0.2% | 0.00% | -50.0% |
| Q1 2019 | $925,344,000 | +71.2% | 13,721 | +17.1% | 0.00% | +100.0% |
| Q4 2018 | $540,455,000 | -25.5% | 11,721 | +24.5% | 0.00% | 0.0% |
| Q3 2018 | $725,853,000 | -6.1% | 9,412 | +2.6% | 0.00% | 0.0% |
| Q2 2018 | $772,810,000 | -6.3% | 9,175 | -9.1% | 0.00% | -50.0% |
| Q1 2018 | $825,078,000 | +43.2% | 10,089 | +0.1% | 0.00% | +100.0% |
| Q4 2017 | $576,159,000 | -29.3% | 10,078 | -17.5% | 0.00% | -50.0% |
| Q3 2017 | $815,418,000 | +16.7% | 12,216 | -10.0% | 0.00% | 0.0% |
| Q2 2017 | $698,434,000 | -9.3% | 13,575 | +2.9% | 0.00% | 0.0% |
| Q1 2017 | $770,296,000 | +64.2% | 13,190 | +17.3% | 0.00% | 0.0% |
| Q4 2016 | $469,045,000 | -38.3% | 11,240 | -21.9% | 0.00% | -33.3% |
| Q3 2016 | $759,974,000 | +51.8% | 14,388 | +20.4% | 0.00% | +50.0% |
| Q2 2016 | $500,621,000 | +2.6% | 11,948 | -0.6% | 0.00% | 0.0% |
| Q1 2016 | $488,093,000 | -60.0% | 12,022 | -36.1% | 0.00% | -33.3% |
| Q4 2015 | $1,221,664,000 | +134.7% | 18,818 | +155.2% | 0.00% | +200.0% |
| Q3 2015 | $520,601,000 | -38.1% | 7,375 | -2.6% | 0.00% | -50.0% |
| Q2 2015 | $841,108,000 | +2485.3% | 7,568 | +2093.6% | 0.00% | – |
| Q1 2015 | $32,534,000 | -46.6% | 345 | -65.3% | 0.00% | – |
| Q3 2014 | $60,982,000 | +3927.9% | 994 | +2661.1% | 0.00% | – |
| Q1 2014 | $1,514,000 | +125.6% | 36 | +28.6% | 0.00% | – |
| Q4 2013 | $671,000 | – | 28 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |